← Back to patent-cliff list
Tazarotene
Tier C — Watch / tradeTazarotene
Allergan
Originator
1996
First approval
-
Expiry (public)
$0.1B ▲
Peak sales
Small molecule
Type
Targets：RAR-β, RAR-γ, RAR-α
Brand：Avage, Suretin, Tazoral, Zorac, Fabior, Tazorac
Indications (approved)：Plaque psoriasis, Acne vulgaris, Psoriasis, 副银屑病
Regional status
US
Approved
1997-06-13
EU
Approved
1996-01-01
China
Approved
2001-01-01
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Tazarotene?
Approved indications include: Plaque psoriasis, Acne vulgaris, Psoriasis, 副银屑病.
When does the Tazarotene patent expire?
No public expiry year is available for Tazarotene yet; this page updates once verified.
How do I get a quote for Tazarotene intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-04